Key facts
- This page summarizes Mardi Dier's Form 4 filing for Adamas Pharmaceuticals Inc.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2021, 16:13.
Mardi Dier - 02 Jun 2021 Form 4 Insider Report for Adamas Pharmaceuticals Inc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 02 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2021, 16:13:53 UTC
- Next SEC filing
- 17 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher B. Prentiss, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mardi Dier filed Form 4 for Adamas Pharmaceuticals Inc on 04 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADMS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- +100%
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 02 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADMS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 02 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $5.21
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
Footnote F2
The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.